The association of microhematuria with mesangial hypercellularity, endocapillary hypercellularity, crescent score and renal outcomes in immunoglobulin A nephropathy
Open Access
- 20 December 2019
- journal article
- research article
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 36 (5) , 840-847
Abstract
Microhematuria is common in immunoglobulin A nephropathy (IgAN). However, current prognostication is based on proteinuria and mesangial hypercellularity, endocapillary hypercellularity, segmental sclerosis, tubulointerstitial fibrosis and crescent (MEST-C) scores. In this retrospective study, we evaluated whether MEST-C score components are associated with the presence of microhematuria at biopsy and whether the degree of microhematuria during follow-up is associated with change in estimated glomerular filtration rate (eGFR), after adjusting for clinical and histological parameters. We identified 125 patients with biopsy-proven IgAN and MEST-C scoring who were not on immunosuppressive therapy at biopsy. Microhematuria was defined as ≥3 red blood cells (RBCs)/high-power field (hpf). Of the 125 patients, 97 had microhematuria at baseline and were more likely to have M1, E1 and C ≥ 1 lesions (P < 0.05 for all) compared with patients without microhematuria. Of the 125 patients, 72 had follow-up data available. An increase in the degree of microhematuria was significantly associated with an eGFR decline of −0.81 mL/min/1.73 m2 [95% confidence interval (CI) −1.44 to −0.19, P = 0.01], after adjusting for follow-up time, proteinuria and T score. Severe microhematuria (≥21 RBCs/hpf) was associated with an even larger decline in eGFR (−3.99 mL/min/1.73 m2; 95% CI −6.9411 to −1.0552, P = 0.008), after similar adjustments. Degree of microhematuria during follow-up is an independent predictor of eGFR decline after adjusting for clinical and histological parameters. Therefore, monitoring the degree of microhematuria as well as proteinuria is important when evaluating patients with IgAN. Additional studies using improvement in microhematuria as a primary surrogate outcome are needed.Keywords
Funding Information
- Clinical and Translational Science Awards (UL1 TR002377)
- National Center for Advancing Translational Sciences
- National Institutes of Health
- NIH
- Mayo Clinic Medical Foundation
This publication has 32 references indexed in Scilit:
- Management and treatment of glomerular diseases (part 1): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies ConferenceKidney International, 2019
- Effect of Oral Methylprednisolone on Clinical Outcomes in Patients With IgA NephropathyJAMA, 2017
- Oxford Classification of IgA nephropathy 2016: an update from the IgA Nephropathy Classification Working GroupKidney International, 2017
- Measures of Urinary Protein and Albumin in the Prediction of Progression of IgA NephropathyClinical Journal of the American Society of Nephrology, 2016
- Effect of hematuria on the outcome of immunoglobulin A nephropathy with proteinuriaJournal of Nephropathology, 2016
- Effect of hematuria on the outcome of IgA nephropathy with mild proteinuriaClinical and Experimental Nephrology, 2014
- Long-Term Outcome of IgA Nephropathy Patients with Recurrent Macroscopic HematuriaAmerican Journal of Nephrology, 2014
- Persistent asymptomatic isolated hematuria in children: clinical and histopathological features and prognosisWorld Journal of Pediatrics, 2013
- Modification and validation of the Birmingham Vasculitis Activity Score (version 3)Annals of the Rheumatic Diseases, 2009
- Immortal Time Bias in PharmacoepidemiologyAmerican Journal of Epidemiology, 2007